Trial Profile

A Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV and MVA-BN-Filo in Infants Aged 4-11 Months in Guinea and Sierra Leone

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
Indications Ebola virus infections
Focus Adverse reactions
Sponsors Janssen Vaccines and Prevention B.V

22 Nov 2022 Status changed from active, no longer recruiting to completed.
02 Aug 2022 Planned primary completion date changed from 28 Jun 2022 to 31 Aug 2022.
07 Jun 2022 Planned End Date changed from 31 Jul 2022 to 9 Sep 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com